Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, weight loss injections such as Mounjaro and Wegovy can produce significant weight reduction without a structured exercise programme — clinical trials consistently show meaningful results even in participants who made no changes to their activity levels. That said, the evidence also shows that adding regular movement amplifies those results and supports long-term maintenance. These are prescription-only medicines, so a clinician needs to assess whether they are right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a question our prescribers hear regularly. Someone has read about Mounjaro or Wegovy, they're not an active person, and they want to know whether the medicine will simply stop working if they don't start running. The honest answer is no, it will not. The large-scale trials that led to UK licensing for both tirzepatide and semaglutide enrolled a wide range of participants, many of whom were sedentary at baseline. The medicines still delivered substantial average weight reductions across those groups.
In the SURMOUNT-1 trial published in the New England Journal of Medicine, adults with obesity taking tirzepatide at 15mg lost an average of around 20–21% of body weight over 72 weeks alongside a reduced-calorie diet, but the protocol did not require participants to meet any specific exercise target. The appetite-suppressing mechanism is independent of whether you lace up your trainers. Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, slowing how quickly the stomach empties and increasing signals of fullness, a process that happens after every meal, not only after a workout. You can read more about the underlying biology on our page covering how weight loss injections work.
So the short version: no, exercise is not a switch that has to be flipped before the medicine does anything. The reduction in appetite, and the calorie deficit that follows, happens whether you are walking 10,000 steps or spending most of the day at a desk.
Here is where the picture becomes more nuanced. Whilst you do not need to be exercising for these medicines to produce results, the clinical evidence is clear that activity improves those results and plays a specific protective role during rapid weight loss.
When the body loses weight quickly, it does not shed only fat. Muscle mass goes too, particularly if protein intake is low and the person is largely inactive. Preserving lean tissue matters for metabolic health, functional strength and for keeping weight off once the medicine is eventually stopped or reduced. Resistance-based activity (even modest strength work twice a week) is consistently associated with better muscle preservation during GLP-1 treatment. That is why NHS England's guidance on weight management injections recommends wraparound support that includes physical activity advice alongside these medicines.
There is also a straightforward numbers point. A calorie deficit achieved through appetite reduction alone will produce weight loss. A calorie deficit combined with activity that burns additional energy will produce a larger deficit. The medicines reduce the numerator; movement can widen the gap further. None of which means you need to join a gym on day one. A daily walk counts. Gradually building activity as energy levels improve (something many patients report as the medicine settles in) is a realistic and clinically sensible path. Our page on weight loss injections and exercise goes into the practical side in more detail.
One framing that patients find useful: think of the injection as handling the appetite side of the equation so that making better choices becomes considerably easier. The medicine removes a lot of the noise, the persistent hunger, the cravings that make a reduced-calorie day feel like a battle of willpower. That headspace, freed up, is where lifestyle changes become achievable rather than theoretical.
People on tirzepatide and semaglutide often report that they naturally start moving more not because they forced themselves to, but because they have more energy and feel less heavy. That is not a side effect listed in the leaflet, it is a commonly reported real-world experience. The clinical trials show what happens under controlled conditions; what happens in practice for many patients is that reduced food intake and gradually increasing activity end up going together without either being prescribed as a requirement.
It is also worth knowing that these medicines are licensed for use alongside a reduced-calorie diet and increased physical activity, that wording in the licence is guidance about the optimal context, not a clause that makes the medicine ineffective if you have not yet hit the gym. Your prescriber will discuss realistic lifestyle goals at assessment, not impose a pass/fail exercise test.
If you are curious about how this treatment might fit your situation specifically, starting a free consultation is the practical next step. A GPhC-registered prescriber reads your answers the same day (not software) and the conversation about activity happens in that clinical context, not as a gatekeeper.
These medicines are prescription-only, which means a prescriber assesses your medical history, current medicines and BMI before treatment begins. Adults with a BMI of 30 or above are typically eligible, as are those with a BMI from 27 upward if they have a weight-related condition such as high blood pressure or type 2 diabetes, though BMI alone never guarantees approval. Lower thresholds can apply for some ethnic backgrounds under UK clinical guidance.
Common side effects are gastrointestinal (nausea, loose stools, indigestion) most noticeable after starting or after a dose increase, and typically settling within a couple of weeks. The NHS medicine information page for tirzepatide covers the full side-effect profile clearly. On a safety note: if you experience severe stomach pain that radiates to the back, seek medical attention promptly, the MHRA highlighted acute pancreatitis as an infrequent but serious possibility with GLP-1 medicines in a January 2026 Drug Safety Update, and that symptom pattern warrants urgent review.
If you are weighing up whether injections are the right route at all, our overview of weight loss without injections covers the alternatives worth knowing about. If you want to understand what a weight loss injection actually involves before committing, our dedicated page walks you through the options available. And if you have seen claims about B12 injections for weight loss, our page on B12 injections and weight loss sets out what the evidence actually says. For those who are particularly cautious about how their body might respond, our guide to the best weight loss injection without side effects compares the available treatments with tolerability in mind.
Treatment, once clinically approved, is dispensed from our GPhC-registered pharmacy and arrives the next working day via DPD, tracked, in plain unbranded packaging. The pen itself is pre-filled and ready to use, no mixing, no special preparation beyond keeping it refrigerated until the day you need it.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.